ESR1 and breast benign neoplasm: The analytical plan, outlined in Figure 3, began with paired end (2x50nt) RNA sequence (RNA-Seq) analysis of polyA+ RNA from a survey panel of samples that consisted of 8 benign breast tumor samples plus 8 each ER+, HER2-positive, and triple negative (TN) primary invasive breast tumors.